Drug companies could come under increased pressure to lower prices in the US, after the opposition Democrat party won control over the lower house in midterm elections.
Novartis says it thinks its one-off gene therapy for spinal muscular atrophy (SMA) could deliver value for money even if its price was set upwards of $4 million – which would set a record f
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.